OrbiMed Advisors STTK Position
ActiveOrbiMed Advisors held their position in Shattuck Labs, Inc. (STTK) in Q4 2025, holding $23.0M worth of shares across 6,306,127 shares.
The position was first reported in Q3 2025 and has been tracked across 2 quarterly 13F filings.
1 other tracked fund also holds STTK.
About Shattuck Labs, Inc.
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Full company profile →Short Interest
2.8%
2.5 days to cover
OrbiMed Advisors STTK Position History
Frequently Asked Questions
Does OrbiMed Advisors own STTK?
Yes. As of Q4 2025, OrbiMed Advisors holds 6,306,127 shares of Shattuck Labs, Inc. (STTK) valued at $23.0M. This data comes from their SEC 13F filing.
How many hedge funds own STTK?
2 specialist biotech hedge funds currently hold STTK, including Redmile Group. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy STTK?
OrbiMed Advisors's position in STTK was first reported in Q3 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's STTK position increasing or decreasing?
OrbiMed Advisors held their STTK position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
STTKCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →